Q & A with EGFR-Mutant Lung Cancer Experts | 2024 Living with EGFR-Mutant Lung Cancer Patient Forum

preview_player
Показать описание
Experts in EGFR-mutant lung cancer answer questions from attendees of the 2024 Living with EGFR-Mutant Lung Cancer Patient Forum hosted by the Chen-Huang Center for EGFR-Mutant Lung Cancers at Dana-Farber Cancer Institute.

  1. Dana-Farber Cancer Institute
  2. Dana-Farber Cancer Institute
  3. DFCI
  4. Dana-Farber
  5. cancer
  6. lung cancer
Рекомендации по теме
Q & A 0:06:02

Q & A with EGFR-Mutant Lung Cancer Experts | 2024 Living with EGFR-Mutant Lung Cancer Patient Fo...

Q & A 0:05:43

Q & A with EGFR-Mutant Lung Cancer Experts | 2023 Living with EGFR-Mutant Lung Cancer Patient Fo...

Future Research and 0:20:38

Future Research and Treatment Options | 2023 Living with EGFR-Mutant Lung Cancer Patient Forum

15 Years of 0:58:47

15 Years of Advances in EGFR Mutant Lung Cancer

Advancing Care for 0:53:55

Advancing Care for Patients With EGFR Mutation–Positive NSCLC: Precision Medicine Strategies

EGFR mutation positive 0:23:10

EGFR mutation positive tumors: Treatment strategies in front line and at relapse

New Treatment Option 0:01:57

New Treatment Option for EGFR Mutated Lung Cancer

Dr. Zhu on 0:02:23

Dr. Zhu on Primary Resistance to Osimertinib in EGFR-Mutant NSCLC

ZENITH20-5: poziotinib for 0:02:51

ZENITH20-5: poziotinib for EGFR/HER2 exon 20 mutant NSCLC

Symptom Management | 0:15:03

Symptom Management | 2023 Living with EGFR-Mutant Lung Cancer Patient Forum

EGFR Lung Cancer 0:02:22

EGFR Lung Cancer Mutations: What's new in treatments?

Brain Metastases in 0:17:00

Brain Metastases in EGFR-Mutant Lung Cancer | 2023 Living with EGFR-Mutant Lung Cancer Patient Forum

Studies on EGFR 0:03:38

Studies on EGFR mutants in NSCLC

Early results from 0:02:51

Early results from a 3rd gen EGFR-TKI in advanced NSCLC

TKI-resistant EGFR-mutant NSCLC 0:20:35

TKI-resistant EGFR-mutant NSCLC

Managing progression in 0:19:53

Managing progression in EGFR-mutant NSCLC patients: Potential impact of 2nd and 3rd generation TKIs?

ASCO 2020: Latest 0:15:35

ASCO 2020: Latest developments in EGFR-mutated non-small cell lung cancer

Watch Drs. Stiles 0:47:31

Watch Drs. Stiles & Yu discuss #EGFR mutated #NSCLC at #ThoracicSummit2022 - https://bit.ly/3y31...

CRSF 07th Masterclass: 0:09:35

CRSF 07th Masterclass: Uncommon EGFR Mutations in Lung Cancer | Dr. Pradeep Ventrapati

2022 Liquid Biopsy 0:43:20

2022 Liquid Biopsy EQA for lung cancer (EGFR) webinar - 28th June 2023

CRSF 07th Masterclass: 0:11:09

CRSF 07th Masterclass: Mechanism of Resistance to Osimertinib in EGFR Mutated Lung Cancer|Dr. Mandal

Afatinib Therapy for 0:03:47

Afatinib Therapy for Uncommon EGFR Alterations in NSCLC

Navigating Rapid Changes 0:59:03

Navigating Rapid Changes in First- and Later-Line Treatment of EGFR-Mutated NSCLC

IMpower150: efficacy outcomes 0:01:31

IMpower150: efficacy outcomes of atezolizumab addition in pre-treated EGFR-mutated NSCLC